NEOIMMUNETECH, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,770 KRW | -4.48% |
|
-7.28% | -12.59% |
| Apr. 02 | NeoImmuneTech, Inc. Announces Chief Executive Officer Changes | CI |
| Jan. 15 | NeoImmuneTech, Inc. Appoints Luke Oh as President | CI |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 40.04B 55,445B |
|---|---|---|---|---|---|
| Net income 2022 | -60.41B -83,644B | Net income 2023 | -53.4B -73,950B | EV / Sales 2022 | - |
| Net cash position 2022 | 112B 155,396B | Net cash position 2023 | 65.16B 90,233B | EV / Sales 2023 | - |
| P/E ratio 2022 |
-6.53
x | P/E ratio 2023 |
-3.75
x | Employees | 100 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
More news
| 1 day | -4.48% | ||
| 1 week | -7.28% | ||
| 1 month | -3.28% | ||
| 3 months | +7.99% | ||
| 6 months | +17.14% | ||
| Current year | -12.59% |
1 week
1 750.00
1 950.00
1 month
1 750.002 120.00
Current year
1 299.002 130.00
1 year
1 180.003 125.00
3 years
1 180.0012 750.00
5 years
1 180.0017 450.00
10 years
1 180.0017 450.00
| Managers | Title | Age | Since |
|---|---|---|---|
Se-Hwan Yang
FOU | Founder | 54 | 13-12-31 |
Tae-Woo Kim
DFI | Director of Finance/CFO | 44 | 18-04-30 |
Dana Wyche
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Se-Hwan Yang
FOU | Founder | 54 | 13-12-31 |
Soo-Hyoung Kang
BRD | Director/Board Member | - | - |
Jung-Won Woo
BRD | Director/Board Member | 64 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 1,770 | -4.48% | 575,043 |
| 24-05-30 | 1,853 | +0.71% | 275,164 |
| 24-05-29 | 1,840 | -4.37% | 536,163 |
| 24-05-28 | 1,924 | -0.52% | 522,938 |
| 24-05-27 | 1,934 | +1.31% | 590,954 |
End-of-day quote Korea S.E., May 30, 2024
More quotes
NeoImmuneTech, Inc. is a clinical-stage T cell-focused biopharmaceutical company. The Company is engaged in the discovery and development of immuno-therapeutics. Its lead asset includes NT-I7 (efineptakin alfa), which is a T Cell Amplifier. NT-I7 is a human IL-7 (Interleukin-7) fusion protein that overcomes the limitations of endogenous IL-7. The IL-7 domain promotes T cell development, which plays a role in the immune response. The N-terminus of the IL-7 domain overcomes its structural instability and enables mass production of NT-I7. NT-I7 is a clinical-stage long-acting human IL-7 and is being developed in oncologic and immunologic indications. It is conducting multiple clinical trials of NT-I7 in multiple indications both as a monotherapy and in combination with other therapeutics, such as checkpoint inhibitors and other. Its products include NIT-106, NIT-109, NIT-110, NIT-119, NIT-120, NIT-104, NIT-107, NIT-112, NIT-105, NIT-108, NIT-113, NIT-114, NIT-115, NIT-116 and NIT-A01.
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -12.59% | 25.31M | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- A950220 Stock
